JP2023547978A5 - - Google Patents
Info
- Publication number
- JP2023547978A5 JP2023547978A5 JP2023510318A JP2023510318A JP2023547978A5 JP 2023547978 A5 JP2023547978 A5 JP 2023547978A5 JP 2023510318 A JP2023510318 A JP 2023510318A JP 2023510318 A JP2023510318 A JP 2023510318A JP 2023547978 A5 JP2023547978 A5 JP 2023547978A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- polypeptide according
- antigen
- cleavable linker
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025078945A JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064268P | 2020-08-11 | 2020-08-11 | |
| US63/064,268 | 2020-08-11 | ||
| PCT/US2021/045395 WO2022035866A1 (en) | 2020-08-11 | 2021-08-10 | Cleavable linker compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078945A Division JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023547978A JP2023547978A (ja) | 2023-11-15 |
| JP2023547978A5 true JP2023547978A5 (cg-RX-API-DMAC7.html) | 2024-08-07 |
| JP7681681B2 JP7681681B2 (ja) | 2025-05-22 |
Family
ID=80223911
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023510318A Active JP7681681B2 (ja) | 2020-08-11 | 2021-08-10 | 切断可能リンカー組成物および方法 |
| JP2025078945A Pending JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078945A Pending JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11512113B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4196488B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7681681B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102944047B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116348597A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021326469C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3187754A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3040950T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001788A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022035866A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111247171A (zh) * | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| US12534734B2 (en) * | 2018-05-15 | 2026-01-27 | Drive Therapeutics Llc | Stem-loop compositions and methods for inhibiting interleukin-8 |
| AU2021326469C1 (en) * | 2020-08-11 | 2026-04-30 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| AR125758A1 (es) | 2021-05-12 | 2023-08-09 | Janux Therapeutics Inc | Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| KR20250024874A (ko) * | 2022-04-04 | 2025-02-19 | 재눅스 테라퓨틱스 인크. | Psma 및 이펙터 세포 항원을 표적으로 하는 종양 활성화 항체와 관련된 조성물 및 방법 |
| WO2024100451A2 (en) * | 2022-11-11 | 2024-05-16 | Janux Therapeutics, Inc. | Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens |
| WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| CN122349537A (zh) | 2023-12-01 | 2026-07-07 | 阿布林克斯有限公司 | 识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体 |
| WO2025201560A1 (en) * | 2024-03-29 | 2025-10-02 | Vibrant Pharma Limited | Multispecific antigen-binding proteins and uses thereof |
| GB2641580A (en) * | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| US20260226165A1 (en) * | 2024-12-17 | 2026-08-06 | Merck Sharp & Dohme Llc | Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US20010031264A1 (en) | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
| JP2009540015A (ja) | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗egfr抗体の凍結乾燥製剤 |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| WO2016077505A2 (en) * | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Cytomx生物製藥公司 | 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法 |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| CN110072890B (zh) | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| AU2017364818C1 (en) * | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| CN112005304A (zh) | 2018-03-20 | 2020-11-27 | 西托姆克斯治疗公司 | 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法 |
| WO2019222282A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP2022512124A (ja) * | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス,インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| US20230220105A1 (en) | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
| WO2020264200A1 (en) | 2019-06-26 | 2020-12-30 | Amunix Pharmceuticals, Inc. | Cd3 antigen binding fragments and compositions comprising same |
| AU2021326469C1 (en) * | 2020-08-11 | 2026-04-30 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
-
2021
- 2021-08-10 AU AU2021326469A patent/AU2021326469C1/en active Active
- 2021-08-10 ES ES21856576T patent/ES3040950T3/es active Active
- 2021-08-10 EP EP21856576.0A patent/EP4196488B1/en active Active
- 2021-08-10 MX MX2023001788A patent/MX2023001788A/es unknown
- 2021-08-10 CA CA3187754A patent/CA3187754A1/en active Pending
- 2021-08-10 US US17/398,500 patent/US11512113B2/en active Active
- 2021-08-10 EP EP25185336.2A patent/EP4631977A3/en active Pending
- 2021-08-10 WO PCT/US2021/045395 patent/WO2022035866A1/en not_active Ceased
- 2021-08-10 KR KR1020237008265A patent/KR102944047B1/ko active Active
- 2021-08-10 CN CN202180069665.6A patent/CN116348597A/zh active Pending
- 2021-08-10 KR KR1020267008789A patent/KR20260042619A/ko active Pending
- 2021-08-10 JP JP2023510318A patent/JP7681681B2/ja active Active
-
2022
- 2022-10-24 US US17/972,348 patent/US20230147782A1/en not_active Abandoned
-
2024
- 2024-09-19 US US18/890,543 patent/US20250019403A1/en not_active Abandoned
-
2025
- 2025-05-09 JP JP2025078945A patent/JP2025131591A/ja active Pending
-
2026
- 2026-02-09 AU AU2026200907A patent/AU2026200907A1/en active Pending